289 related articles for article (PubMed ID: 11406915)
21. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
Borah B; Dufresne TE; Chmielewski PA; Johnson TD; Chines A; Manhart MD
Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
[TBL] [Abstract][Full Text] [Related]
22. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Eastell R; Devogelaer JP; Peel NF; Chines AA; Bax DE; Sacco-Gibson N; Nagant de Deuxchaisnes C; Russell RG
Osteoporos Int; 2000; 11(4):331-7. PubMed ID: 10928223
[TBL] [Abstract][Full Text] [Related]
23. Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.
Watts NB
Osteoporos Int; 2001 Dec; 12 Suppl 3():S17-22. PubMed ID: 11846337
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
26. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Sato Y; Iwamoto J; Kanoko T; Satoh K
Neurology; 2005 Mar; 64(5):811-6. PubMed ID: 15753414
[TBL] [Abstract][Full Text] [Related]
27. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
28. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
[TBL] [Abstract][Full Text] [Related]
29. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
Henderson S; Hoffman N; Prince R
Am J Gastroenterol; 2006 Jan; 101(1):119-23. PubMed ID: 16405543
[TBL] [Abstract][Full Text] [Related]
30. Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats.
Jee WS; Lin BY; Ma YF; Ke HZ
J Bone Miner Res; 1995 Jun; 10(6):963-70. PubMed ID: 7572321
[TBL] [Abstract][Full Text] [Related]
31. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
[TBL] [Abstract][Full Text] [Related]
32. Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.
Dougherty JA
Ann Pharmacother; 2002 Mar; 36(3):512-6. PubMed ID: 11895066
[TBL] [Abstract][Full Text] [Related]
33. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
Chapurlat R; Meunier PJ
Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
[TBL] [Abstract][Full Text] [Related]
34. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site.
Boyce RW; Paddock CL; Gleason JR; Sletsema WK; Eriksen EF
J Bone Miner Res; 1995 Feb; 10(2):211-21. PubMed ID: 7754801
[TBL] [Abstract][Full Text] [Related]
35. [Risedronate: clinical usage].
Shiraki M
Nihon Rinsho; 2002 Mar; 60 Suppl 3():529-37. PubMed ID: 11979951
[No Abstract] [Full Text] [Related]
36. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Reid DM; Adami S; Devogelaer JP; Chines AA
Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
[TBL] [Abstract][Full Text] [Related]
37. Drugs for prevention and treatment of postmenopausal osteoporosis.
Med Lett Drugs Ther; 2000 Oct; 42(1090):97-100. PubMed ID: 11035622
[No Abstract] [Full Text] [Related]
38. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Delmas PD; McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S
Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
[TBL] [Abstract][Full Text] [Related]
39. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Tanriverdi HA; Barut A; Sarikaya S
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):63-8. PubMed ID: 15866088
[TBL] [Abstract][Full Text] [Related]
40. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
Dufresne TE; Chmielewski PA; Manhart MD; Johnson TD; Borah B
Calcif Tissue Int; 2003 Nov; 73(5):423-32. PubMed ID: 12964065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
